KHTRF - Knight Therapeutics enters license supply pacts with Rigel

Knight Therapeutics (OTC:KHTRF) has entered into exclusive license and supply pacts with Rigel Pharmaceuticals granting Knight the rights to commercialize fostamatinib, an oral spleen tyrosine kinase inhibitor, in Latin America. Per the terms, Rigel will receive an upfront cash payment, with the potential for additional regulatory and commercial milestones, and stepped-up royalties based on tiered net sales. Like for like, KHTRF also receives exclusive rights to fostamatinib in all potential indications, including chronic ITP, wAIHA, and COVID-19 in Latin America. Fostamatinib is marketed in U.S. as Tavalisse tablets, and is approved in U.S., Europe, and Canada as a treatment for adult chronic immune thrombocytopenia. Currently, studied in a Phase 3 clinical trial for the treatment of warm autoimmune hemolytic anemia  and in two Phase 3 clinical trials for the treatment of hospitalized patients with COVID-19.

For further details see:

Knight Therapeutics enters license, supply pacts with Rigel